Voyant Beauty's Elkhart, Indiana plant made OTC aerosol drugs contaminated with benzene and failed to investigate or test properly.
What happened
FDA inspected the company's drug manufacturing facility in Elkhart, Indiana, from August 23 to September 2, 2022. Investigators collected samples of three drug products, and FDA lab testing found benzene at 6, 3, and 1 parts per million; the letter also cites benzene as high as 13.3 ppm in the company's drug products. A customer expanded a voluntary nationwide recall to include a contaminated batch because benzene was above 2 ppm.
What FDA found
The company did not properly investigate why its drug products were contaminated with benzene, and kept its look at causes limited to one propellant even after a customer reported benzene in products using a different propellant.
21 CFR 211.192The company did not test many of its topical drug products for microorganisms that would be harmful for their intended use before releasing each batch.
21 CFR 211.165(b)The company did not test every lot of glycerin for diethylene glycol (DEG) and ethylene glycol (EG), which are toxic contaminants, and did not assess finished products made with one such glycerin lot.
21 CFR 211.84(d)(1)The company appears to allow propellant left in tanks that did not meet the benzene limit to be blended with conforming propellant so the final result meets specification.
What FDA wants
FDA tells the company to correct the violations promptly and to reply in writing within 15 working days with what it has done, including a full review of its investigation system, benzene test results for reserve samples still on the U.S. market, its plan for testing benzene before release, and confirmation that no propellant above the benzene limit is blended with other propellant.
Who should pay attention
- brands that contract-manufacture OTC aerosol drugs at this facility
- companies whose cosmetics are made on the same shared equipment
- quality teams releasing products that use glycerin or hydrocarbon propellants
This is a summary. Read the original letter on fda.gov.